

1. Pokhrel KP, Vovoros D, Tsokos CP. Histological and demographic characteristics of the distribution of brain and central nervous system tumors' sizes: results from SEER registries using statistical methods. *Int J Biomed Sci* 2012;8:152–162.
2. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS Statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. *Neuro Oncol* 2013;15:ii–ii56.
3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. *Brain Pathol* 1993;3:255–268.
4. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 2007;114:97–109.
5. Porter KR, McCarthy BJ, Freels S, et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. *Neuro Oncol* 2010;12:520–527.
6. Bondy ML, Scheurer ME, Malmer B, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. *Cancer* 2008;113:1953–1968.
7. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. *Acta Neuropathol* 2005;109:93–108.
8. Sadetzki S, Chetrit A, Freedman L, et al. Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis. *Radiat Res* 2005;163:424–432.
9. Mack EE, Wilson CB. Meningiomas induced by high-dose cranial irradiation. *J Neurosurg* 1993;79:28–31.
10. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. *N Engl J Med* 1991;325:1330–1336.
11. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. *Lancet* 2012;380:499–505.
12. Claus EB, Calvocoressi L, Bondy ML, et al. Dental x-rays and risk of meningioma. *Cancer* 2012;118:4530–4537.
13. Rothman KJ. Health effects of mobile telephones. *Epidemiology* 2009;20:653–655.
14. Hardell L, Carlberg M, Hansson Mild K. Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma. *Pathophysiology* 2013;20:85–110.
15. Corle C, Makale M, Kesari S. Cell phones and glioma risk: a review of the evidence. *J Neurooncol* 2012;106:1–13.
16. Kan P, Simonsen SE, Lyon JL, et al. Cellular phone use and brain tumor: a meta-analysis. *J Neurooncol* 2008;86:71–78.
17. Myung SK, Ju W, McDonnell DD, et al. Mobile phone use and risk of tumors: a meta-analysis. *J Clin Oncol* 2009;27:5565–5572.
18. Ahlbom A, Feychting M, Green A, et al. Epidemiologic evidence on mobile phones and tumor risk: a review. *Epidemiology* 2009;20:639–652.
19. Samkange-Zeeb F, Schlehofer B, Schuz J, et al. Occupation and risk of glioma, meningioma and acoustic neuroma: results from a German case-control study (interphone study group, Germany). *Cancer Epidemiol* 2010;34:55–61.
20. Brenner AV, Linet MS, Selker RC, et al. Polio vaccination and risk of brain tumors in adults: no apparent association. *Cancer Epidemiol Biomarkers Prev* 2003;12:177–178.
21. Cote TR, Manns A, Hardy CR, et al. Epidemiology of brain lymphoma among people with or without acquired immunodeficiency syndrome. AIDS/Cancer Study Group. *J Natl Cancer Inst* 1996;88:675–679.
22. Herndier BG, Kaplan LD, McGrath MS. Pathogenesis of AIDS lymphomas. *AIDS* 1994;8:1025–1049.
23. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. *Cancer Res* 2002;62:3347–3350.
24. Scheurer ME, Bondy ML, Aldape KD, et al. Detection of human cytomegalovirus in different histological types of gliomas. *Acta Neuropathol* 2008;116:79–86.
25. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. *Neuro Oncol* 2012;14:246–255.
26. Dziurzynski K, Wei J, Qiao W, et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. *Clin Cancer Res* 2011;17:4642–4649.
27. Melean G, Sestini R, Ammannati F, et al. Genetic insights into familial tumors of the nervous system. *Am J Med Genet C Semin Med Genet* 2004;129C:74–84.
28. Gu J, Liu Y, Kyritsis AP, et al. Molecular epidemiology of primary brain tumors. *Neurotherapeutics* 2009;6:427–435.
29. Evans DG, Farndon PA, Burnell LD, et al. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. *Br J Cancer* 1991;64:959–961.
30. Springate JE. The nevoid basal cell carcinoma syndrome. *J Pediatr Surg* 1986;21:908–910.
31. Demers PA, Vaughan TL, Schommer RR. Occupation, socioeconomic status, and brain tumor mortality: a death certificate-based case-control study. *J Occup Med* 1991;33:1001–1006.
32. Grayson JK. Radiation exposure, socioeconomic status, and brain tumor risk in the US Air Force: a nested case-control study. *Am J Epidemiol* 1996;143:480–486.
33. Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. *Epidemiol Rev* 1995;17:382–414.
34. Wrensch M, Bondy ML, Wiencke J, et al. Environmental risk factors for primary malignant brain tumors: a review. *J Neurooncol* 1993;17:47–64.
35. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. *J Neuropathol Exp Neurol* 2002;61:215–225.
36. Fujisawa H, Marukawa K, Hasegawa M, et al. Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. *J Neurosurg* 2002;97:1350–1355.
37. Omuro AM, Delattre JY. Editorial: what is new in the treatment of gliomas? *Curr Opin Neurol* 2007;20:704–707.
38. Lu QR, Sun T, Zhu Z, et al. Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. *Cell* 2002;109:75–86.
39. McLendon RE, Provenzale J. Glioneuronal tumors of the central nervous system. *Brain Tumor Pathol* 2002;19:51–58.
40. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. *Genes Dev* 2001;15:1311–1333.
41. Dirks PB. Cancer: stem cells and brain tumours. *Nature* 2006;444:687–688.
42. Friedmann-Morvinski D, Bushong EA, Ke E, et al. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science* 2012;338:1080–1084.
43. Preston-Martin S. Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972–1985. *Neuroepidemiology* 1990;9:106–111.
44. Cha S. Neuroimaging in neuro-oncology. *Neurotherapeutics* 2009;6:465–477.
45. Bardin T, Rchette P. Nephrogenic systemic fibrosis. *Curr Opin Rheumatol* 2010;22:54–58.
46. Omuro AM, Leite CC, Mokhtari K, et al. Pitfalls in the diagnosis of brain tumours. *Lancet Neurol* 2006;5:937–948.
47. Price SJ. Advances in imaging low-grade gliomas. *Adv Tech Stand Neurosurg* 2010;35:1–34.
48. Brandao LA, Shiroishi MS, Law M. Brain tumors: a multimodality approach with diffusion-weighted imaging, diffusion tensor imaging, magnetic resonance spectroscopy, dynamic susceptibility contrast and dynamic contrast-enhanced magnetic resonance imaging. *Magn Reson Imaging Clin N Am* 2013;21:199–239.
49. Gulyas B, Hallidin C. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. *Q J Nucl Med Mol Imaging* 2012;56:173–190.
50. Iskandar BJ, Sansone JM, Medow J, et al. The use of quick-brain magnetic resonance imaging in the evaluation of shunt-treated hydrocephalus. *J Neurosurg* 2004;101:147–151.
51. d'Avella D, Ciccariello R, Angileri FF, et al. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. *Acta Neurochir Suppl* 1998;71:282–284.
52. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. *J Clin Oncol* 2008;26:2192–2197.
53. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol* 2010;28:1963–1972.
54. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg* 2001;95:190–198.
55. McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. *J Neurosurg* 2009;110:156–162.
56. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. *J Neurosurg* 2011;115:3–8.
57. Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of resectability, and effect on survival. *J Neurosurg* 2012;117:851–859.
58. Siomion V, Angelov L, Li L, et al. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. *J Neurooncol* 2005;74:211–215.
59. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. *Can J Neurol Sci* 2003;30:106–112.
60. Barnett GH. Surgical management of convexity and falx meningiomas using interactive image-guided surgery systems. *Neurosurg Clin N Am* 1996;7:279–284.
61. Henry RG, Berman JJ, Nagarajan SS, et al. Subcortical pathways serving cortical language sites: initial experience with diffusion tensor imaging fiber tracking combined with intraoperative language mapping. *Neuroimage* 2004;21:616–622.
62. Hatiboglu MA, Weinberg JS, Suki D, et al. Impact of intraoperative high-field magnetic resonance imaging guidance on glioma surgery: a prospective volumetric analysis. *Neurosurgery* 2009;64:1073–1081.
63. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2006;7:392–401.
64. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. *Neurosurgery* 2012;70:234–243.

65. Henegar MM, Moran CJ, Silbergeld DL. Early postoperative magnetic resonance imaging following nonneoplastic cortical resection. *J Neurosurg* 1996;84:174–179.
66. Barker FG 2nd, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. *Neurosurgery* 1998;42:709–720.
67. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. *J Neurosurg* 2001;95:735–745.
68. Kelly PJ, Daumas-Duport C, Scheithauer BW, et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. *Mayo Clin Proc* 1987;62:450–459.
69. Hermanto U, Frijia EK, Lii MJ, et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? *Int J Radiat Oncol Biol Phys* 2007;67:1135–1144.
70. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. *Int J Radiat Oncol Biol Phys* 2002;52:599–605.
71. Bova FJ, Buatti JM, Friedman WA, et al. The University of Florida frameless high-precision stereotactic radiotherapy system. *Int J Radiat Oncol Biol Phys* 1997;38:875–882.
72. Miranpuri AS, Tome WA, Paliwal BR, et al. Assessment of patient-independent intrinsic error for a noninvasive frame for fractionated stereotactic radiotherapy. *Int J Cancer* 2001;96:320–325.
73. Stieber VW, Bourland JD, Tome WA, et al. Gentlemen (and ladies), choose your weapons: Gamma knife vs. linear accelerator radiosurgery. *Technol Cancer Res Treat* 2003;2:79–86.
74. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. *Int J Radiat Oncol Biol Phys* 2006;65:1–7.
75. Chung CS, Yock TI, Nelson K, et al. Incidence of second malignancies among patients treated with proton versus photon radiation. *Int J Radiat Oncol Biol Phys* 2013;87:46–52.
76. Dempsey JF, Williams JA, Stubbs JB, et al. Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain-tumor resection-cavity margins. *Int J Radiat Oncol Biol Phys* 1998;42:421–429.
77. Lunsford LD, Gumberman L, Levine G. Stereotactic intracavitary irradiation of cystic neoplasms of the brain. *Appl Neurophysiol* 1985;48:146–150.
78. Kobayashi T, Kageyama N, Ohara K. Internal irradiation for cystic craniopharyngioma. *J Neurosurg* 1981;55:896–903.
79. Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. *J Nucl Med* 1989;30:1636–1645.
80. Reardon DA, Zalutsky MR, Akabani G, et al. A pilot study: 131I-antitennascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. *Neuro Oncol* 2008;10:182–189.
81. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. *J Clin Oncol* 2007;25:2295–2305.
82. Smith Q, Fisher C, Allen D. The role of plasma protein binding in drug delivery to brain. In: Kobiler D, Lustig S, Shapira S, eds. *Blood-Brain Barrier*. New York: Springer; 2001:311–321.
83. Groothuis DR. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. *Neuro Oncol* 2000;2:45–59.
84. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. *Neurosurgery* 1998;42:1083–1099.
85. T'ayli A, Hentschel P, Madajewicz S, et al. Toxicities related to intraarterial infusion of cisplatin and etoposide in patients with brain tumors. *J Neurooncol* 1999;42:73–77.
86. Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. *J Drug Target* 2008;16:73–78.
87. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? *Drug Discov Today* 2008;13:1099–1106.
88. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. *J Neurosurg* 1991;74:441–446.
89. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQOR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. *J Clin Oncol* 2007;25:837–844.
90. Patel SJ, Shapiro WR, Laske DW, et al. Safety and feasibility of convection-enhanced delivery of Cytarabine for the treatment of malignant glioma: initial experience in 51 patients. *Neurosurgery* 2005;56:1243–1252.
91. Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas. *Mol Cancer Ther* 2007;6:1909–1919.
92. Chang SM, Lamborn KR, Kuhn JG, et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. *Neuro Oncol* 2008;10:631–642.
93. Huang TT, Sarkaria SM, Cloughesy TF, et al. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. *Neurotherapeutics* 2009;6:500–512.
94. Trippa L, Lee EQ, Wen PY, et al. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. *J Clin Oncol* 2012;30:3258–3263.
95. Fetell MR, Grossman SA, Fisher JD, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. *J Clin Oncol* 1997;15:3121–3128.
96. Grossman SA, Hochberg F, Fisher J, et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. *Cancer Chemother Pharmacol* 1998;42:118–126.
97. Prados MD, Yung WK, Jaeckle KA, et al. Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. *Neuro Oncol* 2004;6:44–54.
98. Prados MD, Lamborn KR, Chang S, et al. Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. *Neuro Oncol* 2006;8:67–78.
99. Cloughesy TF, Kuhn J, Robins HI, et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. *J Clin Oncol* 2005;23:6647–6656.
100. Chang SM, Kuhn JG, Rizzo J, et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. *J Clin Oncol* 1998;16:2188–2194.
101. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathol* 2011;121:397–405.
102. Pollack IF, Claassen D, al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. *J Neurosurg* 1995;82:536–547.
103. Wallner KE, Gonzales MF, Edwards MS, et al. Treatment results of juvenile pilocytic astrocytoma. *J Neurosurg* 1988;69:171–176.
104. Benesch M, Lackner H, Sovinz P, et al. Late sequelae after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003. *J Neurooncol* 2006;78:199–205.
105. Mulhern RK, Palmer SL. Neurocognitive late effects in pediatric cancer. *Curr Probl Cancer* 2003;27:177–197.
106. Shaw EG, Daumas-Duport C, Scheithauer BW, et al. Radiation therapy in the management of low-grade supratentorial astrocytomas. *J Neurosurg* 1989;70:853–861.
107. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2013;381:125–132.
108. Louis DN. Molecular pathology of malignant gliomas. *Annu Rev Pathol* 2006;1:97–117.
109. Yan H, Bigner DD, Velculescu V, et al. Mutant metabolic enzymes are at the origin of gliomas. *Cancer Res* 2009;69:9157–9159.
110. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 2009;360:765–773.
111. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. *Nat Med* 2012;18:624–629.
112. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. *J Clin Oncol* 2009;27:4150–4154.
113. Leu S, von Felten S, Frank S, et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. *Neuro Oncol* 2013;15:469–479.
114. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. *Cancer Res* 2006;66:9852–9861.
115. Weiler M, Wick W. Molecular predictors of outcome in low-grade glioma. *Curr Opin Neurol* 2012;25:767–773.
116. Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. *J Clin Oncol* 2002;20:2076–2084.
117. Gorlia T, Wu W, Wang M, et al. New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. *Neuro Oncol* 2013;15:1568–1579.
118. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. *J Neurosurg* 2008;109:835–841.
119. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. *Lancet* 2005;366:985–990.
120. Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. *Int J Radiat Oncol Biol Phys* 1996;36:549–556.
121. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. *J Clin Oncol* 2002;20:2267–2276.

122. Gondi V, Eickhoff J, Tome W, et al. Absence of survival benefit from early adjuvant radiotherapy (EART) for resected supratentorial low-grade glioma (SLGG) in adults: A SEER database analysis. *Int J Radiat Oncol Biol Phys* 2011;S270 (Abstract # 2120).
123. Brown PD, Buckner JC, Uhm JH, et al. The neurocognitive effects of radiation in adult low-grade glioma patients. *Neuro Oncol* 2003;5:161–167.
124. Laack NN, Brown PD, Ivnik RJ, et al. Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. *Int J Radiat Oncol Biol Phys* 2005;63:1175–1183.
125. Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. *Int J Radiat Oncol Biol Phys* 2013;85:348–354.
126. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. *J Clin Oncol* 2004;22:3133–3138.
127. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. *J Clin Oncol* 2003;21:646–651.
128. Packer RJ, Sutton LN, Bilaniuk LT, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. *Ann Neurol* 1988;23:79–85.
129. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. *J Neurosurg* 1997;86:747–754.
130. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. *Pediatr Blood Cancer* 2009;52:791–795.
131. Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. *Cancer* 2005;103:2636–2642.
132. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. *J Clin Oncol* 2012;30:1358–1363.
133. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. *Ann Neurol* 2006;59:490–498.
134. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. *Neuro Oncol* 2003;5:153–160.
135. Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. *J Clin Oncol* 2012;30:3065–3070.
136. Buckner JC, Pugh SL, Shaw EG, et al. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. *J Clin Oncol* 2014;32:abstract 2000.
137. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. *J Clin Oncol* 2003;21:2525–2528.
138. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. *Ann Oncol* 2003;14:1722–1726.
139. Soffietti R, Ruda R, Bradac GB, et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. *Neurosurgery* 1998;43:1066–1073.
140. Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. *Cancer* 2005;103:802–809.
141. Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. *Eur J Neurol* 2007;14:391–398.
142. Buckner JC, Gesme D Jr, O'Fallon JR, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendrogloma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. *J Clin Oncol* 2003;21:251–255.
143. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendrogloma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. *Ann Oncol* 2003;14:599–602.
144. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. *Ann Oncol* 2003;14:1715–1721.
145. Murphy PS, Viviers L, Abson C, et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. *Br J Cancer* 2004;90:781–786.
146. Pouratian N, Casco J, Sherman JH, et al. Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. *J Neurooncol* 2007;82:281–288.
147. Fisher BJ, Lui J, Macdonald DR, et al. A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: preliminary results of RTOG 0424. *J Clin Oncol* 2013;31(15 suppl):abstr 2008.
148. Baumert BG, Mason WP, Ryan C, et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033). *J Clin Oncol* 2013;31(suppl):abstr 2007.
149. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. *Neuro Oncol* 2007;9:271–279.
150. McBride SM, Perez DA, Polley MY, et al. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. *J Neurooncol* 2010;97:33–40.
151. Prados MD, Scott C, Curran WJ Jr, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. *J Clin Oncol* 1999;17:3389–3395.
152. Leibel SA, Sheline GE. Radiation therapy for neoplasms of the brain. *J Neurosurg* 1987;66:1–22.
153. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUDR for treatment of anaplastic astrocytoma: final report of RTOG 9404. *Int J Radiat Oncol Biol Phys* 2004;58:1147–1152.
154. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet* 2002;359:1011–1018.
155. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. *J Clin Oncol* 2001;19:509–518.
156. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *J Clin Oncol* 2009;27:5874–5880.
157. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 2005;352:997–1003.
158. Balm J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 2008;116:597–602.
159. Levin VA, Hess KR, Choucair A, et al. Phase III randomized study of post-radiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. *Clin Cancer Res* 2003;9:981–990.
160. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. *J Clin Oncol* 1999;17:2762–2771.
161. Chamberlain MC, Wei-Tsao DD, Blumenthal DT, et al. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma. *Cancer* 2008;112:2038–2045.
162. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol* 2009;27:4733–4740.
163. Chamberlain MC, Johnston S. Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma. *J Neurooncol* 2009;91:359–367.
164. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. *Ann Neurol* 1988;23:360–364.
165. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1994;12:2013–2021.
166. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. *J Clin Oncol* 2006;24:2707–2714.
167. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol* 2013;31:337–343.
168. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. *J Clin Oncol* 2006;24:2715–2722.
169. van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. *J Clin Oncol* 2009;27:5881–5886.
170. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. *Neuro Oncol* 2009;11:737–746.
171. van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol* 2013;31:344–350.
172. Vogelbaum MA, Berkey B, Peereboom D, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. *Neuro Oncol* 2009;11:167–175.
173. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. *J Clin Oncol* 2001;19:2449–2455.
174. Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. *Neuro Oncol* 2001;3:193–200.



175. Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people—a randomised study. *Acta Neurochir (Wien)* 2003;145:5–10.
176. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008;321:1807–1812.
177. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006;9:157–173.
178. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 2010;17:98–110.
179. Dunn GP, Rinne ML, Wykosky J, et al. Emerging insights into the molecular and cellular basis of glioblastoma. *Genes Dev* 2012;26:756–784.
180. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. *J Neurosurg* 1978;49:333–343.
181. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase iii clinical trial. *J Clin Oncol* 2013;31:4085–4091.
182. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. *Int J Radiat Oncol Biol Phys* 1979;5:1725–1731.
183. Muacevic A, Kreth FW. Quality-adjusted survival after tumor resection and/or radiation therapy for elderly patients with glioblastoma multiforme. *J Neurol* 2003;250:561–568.
184. Phillips C, Guiney M, Smith J, et al. A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. *Radiother Oncol* 2003;68:23–26.
185. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. *Lancet Oncol* 2012;13:707–715.
186. Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. *Lancet Oncol* 2012;13:916–926.
187. Tsien C, Moughan J, Michalski JM, et al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. *Int J Radiat Oncol Biol Phys* 2009;73:699–708.
188. Tsien CI, Brown D, Normolle D, et al. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. *Clin Cancer Res* 2012;18:273–279.
189. Brachman DG, Wang M, Ashby LS, et al. Phase II trial of temozolomide (tmz), motexafin gadolinium (mgd), and 60 Gy fractionated radiation (rt) for newly diagnosed supratentorial glioblastoma (gbm): results of RTOG 0513. *Int J Radiat Oncol Biol Phys* 2011;81:S129–S130.
190. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987–996.
191. Clarke JL, Iwamoto FM, Sul J, et al. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. *J Clin Oncol* 2009;27:3861–3867.
192. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. *J Clin Oncol* 2010;28:2051–2057.
193. Chalmers AJ. The potential role and application of PARP inhibitors in cancer treatment. *Br Med Bull* 2009;89:23–40.
194. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. *Int J Radiat Oncol Biol Phys* 2008;72:1188–1197.
195. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. *Eur J Cancer* 2010;46:9–20.
196. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. *Neuro Oncol* 2003;5:79–88.
197. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. *J Clin Oncol* 1999;17:2572–2578.
198. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. *Int J Radiat Oncol Biol Phys* 2006;65:1192–1199.
199. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. *J Clin Oncol* 2004;22:133–142.
200. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. *J Clin Oncol* 2009;27:1268–1274.
201. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N Engl J Med* 2005;353:2012–2024.
202. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. *J Clin Oncol* 2009;27:579–584.
203. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. *J Clin Oncol* 2008;26:5603–5609.
204. Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. *Int J Radiat Oncol Biol Phys* 2013;85:1206–1211.
205. Eisenstat DD, Nabors LB, Mason WP, et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. *J Clin Oncol* 2011;29:2010.
206. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. *Invest New Drugs* 2005;23:357–361.
207. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. *J Clin Oncol* 2006;24:3651–3656.
208. Doherty L, Gigas DC, Kesari S, et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. *Neurology* 2006;67:156–158.
209. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. *J Clin Oncol* 2005;23:5294–5304.
210. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. *J Neurooncol* 2010;96:219–230.
211. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. *Clin Cancer Res* 2007;13:1253–1259.
212. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol* 2009;27:740–745.
213. Taal W, Oosterkamp HM, Walenkamp AE, et al. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study. *J Clin Oncol* 2013;31:2001.
214. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. *Int J Radiat Oncol Biol Phys* 2008;71:1372–1380.
215. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med* 2014;370:699–708.
216. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med* 2014;370:709–722.
217. Herrlinger U, Schaefer N, Steinbach JP, et al. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial. *J Clin Oncol* 2013;31:LBA2000.
218. Batchelor TT, Sorensen AC, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. *Cancer Cell* 2007;11:83–95.
219. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. *J Clin Oncol* 2013;31:3212–3218.
220. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. *J Clin Oncol* 2011;29:2689–2695.
221. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. *J Clin Oncol* 2008;26:5610–5617.
222. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. *J Clin Oncol* 2010;28:2712–2718.
223. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. *ASCO Meeting Abstracts* 2013;31:LBA2009.
224. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. *J Clin Oncol* 2010;28:1168–1174.
225. Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). *ASCO Meeting Abstracts* 2010;28:2006.
226. Wick W, Steinbach JP, Platten M, et al. Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. *Neuro Oncol* 2013;15:1405–1412.
227. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. *J Clin Oncol* 2009;27:2052–2058.

228. Kubicek GJ, Werner-Wasik M, Machty M, et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. *Int J Radiat Oncol Biol Phys* 2009;74:433–439.
229. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. *J Clin Oncol* 2009;27:4155–4161.
230. Westphal M, Yla-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2013;14:823–833.
231. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. *J Clin Oncol* 2010;28:4722–4729.
232. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with (alpha)-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J Clin Oncol* 2011;29:330–336.
233. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabectedin: results of a randomized and controlled phase IIb study. *Neuro Oncol* 2011;13:132–142.
234. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. *J Natl Cancer Inst* 1993;85:704–710.
235. Lewis RA, Gerson LP, Axelson KA, et al. von Recklinghausen neurofibromatosis. II. Incidence of optic gliomas. *Ophthalmology* 1984;91:929–935.
236. Kornreich L, Blaser S, Schwarz M, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. *AJNR Am J Neuroradiol* 2001;22:1963–1969.
237. Hemaiz Driever P, von Hornstein S, Pietsch T, et al. Natural history and management of low-grade glioma in NF-1 children. *J Neurooncol* 2010;100:199–207.
238. Parsa CF, Hoyt CS, Lesser RL, et al. Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging. *Arch Ophthalmol* 2001;119:516–529.
239. Fouladi M, Grant R, Baruchel S, et al. Comparison of survival outcomes in patients with intracranial germinomas treated with radiation alone versus reduced-dose radiation and chemotherapy. *Childs Nerv Syst* 1998;14:596–601.
240. Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. *Am J Ophthalmol* 2001;131:442–445.
241. Chan MY, Foong AP, Heisey DM, et al. Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis. *Pediatr Neurosurg* 1998;29:23–28.
242. Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. *Neuro Oncol* 2007;9:430–437.
243. Opocher E, Kremer LC, Da Dalt L, et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. *Eur J Cancer* 2006;42:1807–1816.
244. Tihan T, Fisher PG, Kepner JL, et al. Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. *J Neuropathol Exp Neurol* 1999;58:1061–1068.
245. Grill J, Laithier V, Rodriguez D, et al. When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. *Eur J Pediatr* 2000;159:692–696.
246. Czyzyk E, Jozwiak S, Roszkowski M, et al. Optic pathway gliomas in children with and without neurofibromatosis 1. *J Child Neurol* 2003;18:471–478.
247. Khafaga Y, Hassounah M, Kandil A, et al. Optic gliomas: a retrospective analysis of 50 cases. *Int J Radiat Oncol Biol Phys* 2003;56:807–812.
248. Tenny RT, Laws ER Jr, Younge BR, et al. The neurosurgical management of optic glioma. Results in 104 patients. *J Neurosurg* 1982;57:452–458.
249. Jenkin D, Angyalfi S, Becker L, et al. Optic glioma in children: surveillance, resection, or irradiation? *Int J Radiat Oncol Biol Phys* 1993;25:215–225.
250. Wong JY, Uhl V, Wara WM, et al. Optic gliomas. A reanalysis of the University of California, San Francisco experience. *Cancer* 1987;60:1847–1855.
251. Bataini JP, Delanian S, Ponvert D. Chiasmal gliomas: results of irradiation management in 57 patients and review of literature. *Int J Radiat Oncol Biol Phys* 1991;21:615–623.
252. Rodriguez LA, Edwards MS, Levin VA. Management of hypothalamic gliomas in children: an analysis of 33 cases. *Neurosurgery* 1990;26:242–246.
253. Debus J, Kocagoncu KO, Hoss A, et al. Fractionated stereotactic radiotherapy (FSRT) for optic glioma. *Int J Radiat Oncol Biol Phys* 1999;44:243–248.
254. Jahraus CD, Tarbell NJ. Optic pathway gliomas. *Pediatr Blood Cancer* 2006;46:586–596.
255. Cappelli C, Grill J, Raquin M, et al. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. *Arch Dis Child* 1998;79:334–338.
256. Pierce SM, Barnes PD, Loeffler JS, et al. Definitive radiation therapy in the management of symptomatic patients with optic glioma. Survival and long-term effects. *Cancer* 1990;65:45–52.
257. Donahue B. Short- and long-term complications of radiation therapy for pediatric brain tumors. *Pediatr Neurosurg* 1992;18:207–217.
258. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. *J Clin Oncol* 2006;24:2570–2575.
259. Lacaze E, Kieffer V, Streri A, et al. Neuropsychological outcome in children with optic pathway tumours when first-line treatment is chemotherapy. *Br J Cancer* 2003;89:2038–2044.
260. Gnekow AK, Kaatsch P, Kortmann R, et al. [HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood—an interim report]. *Klin Padiatr* 2000;212:177–184.
261. Ater J, Holmes E, Zhou T, et al. Results of the COG protocol 9952: a randomized phase 3 study of 2 chemotherapy regimens for incompletely resected low grade glioma in young children. *Neuro-Oncology* 2008;10:452.
262. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. *J Clin Oncol* 2002;20:4209–4216.
263. Massimino M, Spreafico F, Riva D, et al. A lower-dose, lower-toxicity cisplatin-etoposide regimen for childhood progressive low-grade glioma. *J Neurooncol* 2010;100:65–71.
264. Sawamura Y, Kamoshima Y, Kato T, et al. Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children. *Jpn J Clin Oncol* 2009;39:277–283.
265. Kuo DJ, Weiner HL, Wisoff J, et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. *J Pediatr Hematol Oncol* 2003;25:372–378.
266. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. *Neuro Oncol* 2007;9:161–168.
267. Khaw SL, Coleman LT, Downie PA, et al. Temozolomide in pediatric low-grade glioma. *Pediatr Blood Cancer* 2007;49:808–811.
268. Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. *Eur J Cancer* 2010;46:2253–2259.
269. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. *J Clin Oncol* 2006;24:1266–1272.
270. Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: prognostic factors and classification. *Brain* 2001;124:2528–2539.
271. Allen JC, Bloom J, Ertel I, et al. Brain tumors in children: current cooperative and institutional chemotherapy trials in newly diagnosed and recurrent disease. *Semin Oncol* 1986;13:110–122.
272. Albright AL. Diffuse brainstem tumors: when is a biopsy necessary? *Pediatr Neurosurg* 1996;24:252–255.
273. Mursch K, Halatsch ME, Markakis E, et al. Intrinsic brainstem tumours in adults: results of microneurosurgical treatment of 16 consecutive patients. *Br J Neurosurg* 2005;19:128–136.
274. Daglioglu E, Cataltepe O, Akalan N. Tectal gliomas in children: the implications for natural history and management strategy. *Pediatr Neurosurg* 2003;38:223–231.
275. Khatib ZA, Heideman RL, Kovnar EH, et al. Predominance of pilocytic histology in dorsally exophytic brain stem tumors. *Pediatr Neurosurg* 1994;20:2–210.
276. Weiner HL, Freed D, Woo HH, et al. Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome. *Pediatr Neurosurg* 1997;27:12–18.
277. Kestle J, Townsend JJ, Brockmeyer DL, et al. Juvenile pilocytic astrocytoma of the brainstem in children. *J Neurosurg* 2004;101:1–6.
278. Freeman CR, Suissa S. Brain stem tumors in children: results of a survey of 62 patients treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 1986;12:1823–1828.
279. Freeman CR, Krischer JP, Sanford RA, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. *Int J Radiat Oncol Biol Phys* 1993;27:197–206.
280. Selvapandian S, Rajshekhar V, Chandy MJ. Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults. *Acta Neurochir (Wien)* 1999;141:721–726.
281. Guillamo JS, Doz F, Delattre JY. Brain stem gliomas. *Curr Opin Neurol* 2001;14:711–715.
282. Khuong-Quang DA, Buczkwicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. *Acta Neuropathol* 2012;124:439–447.
283. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. *Nature* 2012;482:226–231.
284. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. *J Clin Oncol* 2010;28:1337–1344.
285. Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multi-institutional study (SJHG-98). *Cancer* 2005;103:133–139.
286. Lashford LS, Thiess P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. *J Clin Oncol* 2002;20:4684–4691.

287. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. *Cancer* 2007;110:1542–1550.
288. Humphreys R. Posterior cranial fossa brain tumors in children. In: Appuzzo MLJ, ed. *Surgery of the Third Ventricle*. Baltimore: Williams & Wilkins; 1987:872.
289. Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nat Genet* 2013;45:927–932.
290. Jones DT, Kocalkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Cancer Res* 2008;68:8673–8677.
291. Burkhard C, Di Patre PL, Schuler D, et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. *J Neurosurg* 2003;98:1170–1174.
292. Fernandez C, Figarella-Branger D, Girard N, et al. Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. *Neurosurgery* 2003;53:544–553.
293. Gururangan S, Cavazos CM, Ashley D, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. *J Clin Oncol* 2002;20:2951–2958.
294. Mahoney DH Jr, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. *Neuro Oncol* 2000;2:213–220.
295. Lang F. Low-grade gliomas: evidence-based treatment options. In: DeMonte F, Gilbert M, Mahajan A, et al., eds. *Tumors of the Brain and Spine*. New York: Springer; 2007:93–119.
296. Giulioni M, Gardella E, Rubboli G, et al. Lesionectomy in epileptogenic gangliogliomas: seizure outcome and surgical results. *J Clin Neurosci* 2006;13:529–535.
297. Im SH, Chung CK, Cho BK, et al. Intracranial ganglioglioma: preoperative characteristics and oncologic outcome after surgery. *J Neurooncol* 2002;59:173–183.
298. Luyken C, Blumcke I, Fimmers R, et al. Supratentorial ganglioglioma: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. *Cancer* 2004;101:146–155.
299. Compton JJ, Laack NN, Eckel LJ, et al. Long-term outcomes for low-grade intracranial ganglioglioma: 30-year experience from the Mayo Clinic. *J Neurosurg* 2012;117:825–830.
300. Ogiwara H, Nordli DR, DiPatri AJ, et al. Pediatric epileptogenic gangliogliomas: seizure outcome and surgical results. *J Neurosurg Pediatr* 2010;5:271–276.
301. Liauw SL, Byer JE, Yachnis AT, et al. Radiotherapy after subtotally resected or recurrent ganglioglioma. *Int J Radiat Oncol Biol Phys* 2007;67:244–247.
302. Rades D, Zwick L, Leppert J, et al. The role of postoperative radiotherapy for the treatment of gangliogliomas. *Cancer* 2010;116:432–442.
303. Mack SC, Taylor MD. The genetic and epigenetic basis of ependymoma. *Childs Nerv Syst* 2009;25:1195–1201.
304. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. *Cancer Cell* 2005;8:323–35.
305. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. *Nature* 2010;466:632–636.
306. Yao Y, Mack SC, Taylor MD. Molecular genetics of ependymoma. *Chin J Cancer* 2011;30:669–681.
307. Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell* 2011;20:143–157.
308. Ellison DW, Kocak M, Figarella-Branger D, et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. *J Negat Results Biomed* 2011;10:7.
309. Healey EA, Barnes PD, Kupsky WJ, et al. The prognostic significance of postoperative residual tumor in ependymoma. *Neurosurgery* 1991;28:666–671.
310. Jaing TH, Wang HS, Tsay PK, et al. Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. *J Neurooncol* 2004;68:255–261.
311. Vinchon M, Leblond P, Noudel R, et al. Intracranial ependymomas in childhood: recurrence, reoperation, and outcome. *Childs Nerv Syst* 2005;21:221–226.
312. Merchant TE, Li C, Xiong X, et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. *Lancet Oncol* 2009;10:258–266.
313. Shaw EG, Evans RG, Scheithauer BW, et al. Postoperative radiotherapy of intracranial ependymoma in pediatric and adult patients. *Int J Radiat Oncol Biol Phys* 1987;13:1457–1462.
314. Wallner KE, Wara WM, Sheline GE, et al. Intracranial ependymomas: results of treatment with partial or whole brain irradiation without spinal irradiation. *Int J Radiat Oncol Biol Phys* 1986;12:1937–1941.
315. Robertson PL, Zeltzer PM, Boyett JM, et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. *J Neurosurg* 1998;88:695–703.
316. Sutton LN, Goldwein J, Perilongo G, et al. Prognostic factors in childhood ependymomas. *Pediatr Neurosurg* 1990;16:57–65.
317. Pollack IF, Gerszten PC, Martinez AJ, et al. Intracranial ependymomas of childhood: long-term outcome and prognostic factors. *Neurosurgery* 1995;37:655–666.
318. Duffner PK, Kun LE, Burger PC, et al. Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. *Pediatr Neurosurg* 1995;22:189–196.
319. Merchant TE, Fouladi M. Ependymoma: new therapeutic approaches including radiation and chemotherapy. *J Neurooncol* 2005;75:287–299.
320. Bouffet E, Perilongo G, Canete A, et al. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. *Med Pediatr Oncol* 1998;30:319–329.
321. Sandri A, Massimino M, Mastrodicasa L, et al. Treatment with oral etoposide for childhood recurrent ependymomas. *J Pediatr Hematol Oncol* 2005;27:486–490.
322. Turner CD, Gururangan S, Eastwood J, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. *Neuro Oncol* 2002;4:102–108.
323. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. *Am J Surg Pathol* 1997;21:1455–1465.
324. Perry A. Unmasking the secrets of meningioma: a slow but rewarding journey. *Surg Neurol* 2004;61:171–173.
325. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. *J Neurosurg* 2006;105:538–543.
326. Oya S, Kim SH, Sade B, et al. The natural history of intracranial meningiomas. *J Neurosurg* 2011;114:1250–1256.
327. Kai Y, Hamada J, Morioka M, et al. Appropriate interval between embolization and surgery in patients with meningioma. *AJNR Am J Neuroradiol* 2002;23:139–142.
328. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. *J Neurol Neurosurg Psychiatry* 1957;20:22–39.
329. Kinjo T, al-Mefty O, Kanaan I. Grade zero removal of supratentorial convexity meningiomas. *Neurosurgery* 1993;33:394–399.
330. Mirmanoff RO, Dosoretz DE, Linggood RM, et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. *J Neurosurg* 1985;62:18–24.
331. Condra KS, Buatti JM, Mendenhall WM, et al. Benign meningiomas: primary treatment selection affects survival. *Int J Radiat Oncol Biol Phys* 1997;39:427–436.
332. Pollock BE, Stafford SL, Link MJ. Gamma knife radiosurgery for skull base meningiomas. *Neurosurg Clin N Am* 2000;11:659–666.
333. Stafford SL, Perry A, Suman VJ, et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. *Mayo Clin Proc* 1998;73:936–942.
334. Goldsmith BJ, Wara WM, Wilson CB, et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. *J Neurosurg* 1994;80:195–201.
335. Connell PP, Macdonald RL, Mansur DB, et al. Tumor size predicts control of benign meningiomas treated with radiotherapy. *Neurosurgery* 1999;44:1194–1199.
336. Karlsson U, Leibel S, Ke W. Brain tumors. In: Perez C, Brady L, eds. *Principles and Practice of Radiation Oncology*. Philadelphia: Lippincott Williams & Wilkins; 1992:1544.
337. Milosevic MF, Frost PJ, Laperriere NJ, et al. Radiotherapy for atypical or malignant intracranial meningioma. *Int J Radiat Oncol Biol Phys* 1996;34:817–822.
338. Wilson CB. Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. The Richard C. Schneider Lecture. *J Neurosurg* 1994;81:666–675.
339. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. *Int J Radiat Oncol Biol Phys* 1990;18:755–761.
340. Debus J, Wuendrich M, Pirzkall A, et al. High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. *J Clin Oncol* 2001;19:3547–3553.
341. Narayan S, Cornblath WT, Sandler HM, et al. Preliminary visual outcomes after three-dimensional conformal radiation therapy for optic nerve sheath meningioma. *Int J Radiat Oncol Biol Phys* 2003;56:537–543.
342. Turbin RE, Thompson CR, Kennerdell JS, et al. A long-term visual outcome comparison in patients with optic nerve sheath meningioma managed with observation, surgery, radiotherapy, or surgery and radiotherapy. *Ophthalmology* 2002;109:890–899.
343. Engenhart R, Kimmig BN, Hover KH, et al. Stereotactic single high dose radiation therapy of benign intracranial meningiomas. *Int J Radiat Oncol Biol Phys* 1990;19:1021–1026.
344. Kondziolka D, Lunsford LD, Coffey RJ, et al. Stereotactic radiosurgery of meningiomas. *J Neurosurg* 1991;74:552–559.
345. Kondziolka D, Nathoo N, Flickinger JC, et al. Long-term results after radiosurgery for benign intracranial tumors. *Neurosurgery* 2003;53:815–821.
346. Morita A, Coffey RJ, Foote RL, et al. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. *J Neurosurg* 1999;90:42–49.
347. Grunberg S, Rankin C, Townsend J, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. *Proc Am Soc Clin Oncol* 2001;20:222.
348. Grunberg SM, Weiss MH, Spitz IM, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. *J Neurosurg* 1991;74:861–866.



349. Schrell UM, Rittig MG, Anders M, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. *J Neurosurg* 1997;86:840–844.
350. Mason WP, Gentili F, Macdonald DR, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. *J Neurosurg* 2002;97:341–346.
351. Kaba SE, DeMonte F, Bruner JM, et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. *Neurosurgery* 1997;40:271–275.
352. Kaley TJ, Wen PY, Schiff D, et al. Phase II Trial of Sunitinib (SU011248) for recurrent meningioma. *Neuro Oncol* 2010;12(s4):iv75–iv76.
353. Grimm SA, Chamberlain MC, Chandler J, et al. A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. *ASCO Meeting Abstracts* 2011;29:2046.
354. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. *J Neurooncol* 2010;96:211–217.
355. Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). *Neuro Oncol* 2009;11:853–860.
356. Manjila S, Ray A, Hu Y, et al. Embryonal tumors with abundant neuropil and true rosettes: 2 illustrative cases and a review of the literature. *Neurosurg Focus* 2011;30:E2.
357. Gottardo NG, Hansford JR, McGlade JP, et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. *Acta Neuropathol* 2014;127:189–201.
358. Wang X, Ramaswamy V, Remke M, et al. Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. *Neurosurgery* 2013;60:57–63.
359. Northcott PA, Dubuc AM, Pfister S, et al. Molecular subgroups of medulloblastoma. *Expert Rev Neurother* 2012;12:871–884.
360. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature* 2012;488:49–56.
361. Northcott PA, Korshunov A, Pfister SM, et al. The clinical implications of medulloblastoma subgroups. *Nat Rev Neurol* 2012;8:340–351.
362. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. *Cancer Genet* 2011;204:577–588.
363. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. *J Clin Oncol* 2011;29:1408–1414.
364. Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. *Neurosurgery* 2000;47:623–631.
365. Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. *Int J Radiat Oncol Biol Phys* 2007;68:433–440.
366. Attard TM, Giglio P, Koppula S, et al. Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. *Cancer* 2007;109:761–766.
367. Kleihues P, Sobin LH. World Health Organization classification of tumors. *Cancer* 2000;88:2887.
368. McLendon RE, Friedman HS, Fuchs HE, et al. Diagnostic markers in paediatric medulloblastoma: a Paediatric Oncology Group Study. *Histopathology* 1999;34:154–162.
369. Kasetos CD, Liu HM, Zacks SI. Immunohistochemical and ultrastructural observations on Homer Wright (neuroblastic) rosettes and the “pale islands” of human cerebellar medulloblastomas. *Hum Pathol* 1988;19:1219–1227.
370. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. *Nat Rev Cancer* 2012;12:818–834.
371. Nelson M, Diebler C, Forbes WS. Paediatric medulloblastoma: atypical CT features at presentation in the SIOP II trial. *Neuroradiology* 1991;33:140–142.
372. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation. *Radiographics* 2003;23:1613–1637.
373. Kan P, Liu JK, Hedlund G, et al. The role of diffusion-weighted magnetic resonance imaging in pediatric brain tumors. *Childs Nerv Syst* 2006;22:1435–1439.
374. Schneider JF, Viola A, Confort-Gouny S, et al. Infratentorial pediatric brain tumors: the value of new imaging modalities. *J Neuroradiol* 2007;34:49–58.
375. Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. *Radiology* 1969;93:1351–1359.
376. Gajjar A, Fouladi M, Walter AW, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. *J Clin Oncol* 1999;17:1825–1828.
377. Fouladi M, Gajjar A, Boyett JM, et al. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. *J Clin Oncol* 1999;17:3234–3237.
378. Kramer ED, Vezina LG, Packer RJ, et al. Staging and surveillance of children with central nervous system neoplasms: recommendations of the Neurology and Tumor Imaging Committees of the Children’s Cancer Group. *Pediatr Neurosurg* 1994;20:254–262.
379. McManamy CS, Lamont JM, Taylor RE, et al. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. *J Neuropathol Exp Neurol* 2003;62:627–632.
380. Jakacki R, Burger P, Zhou T, et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. *ASCO Meeting Abstracts* 2007;25:2017.
381. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. *J Clin Oncol* 1999;17:832–845.
382. Evans AE, Jenkin RD, Spoto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. *J Neurosurg* 1990;72:572–582.
383. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. *N Engl J Med* 2005;352:978–986.
384. Culley DJ, Berger MS, Shaw D, et al. An analysis of factors determining the need for ventriculoperitoneal shunts after posterior fossa tumor surgery in children. *Neurosurgery* 1994;34:402–407.
385. Lee M, Wisoff JH, Abbott R, et al. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting. *Pediatr Neurosurg* 1994;20:240–247.
386. Berger MS, Baumeister B, Geyer JR, et al. The risks of metastases from shunting in children with primary central nervous system tumors. *J Neurosurg* 1991;74:872–877.
387. Albright AL, Wisoff JH, Zeltzer PM, et al. Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. *Neurosurgery* 1996;38:265–271.
388. Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. *J Neurosurg* 2006;105:444–451.
389. Hughes EN, Shillito J, Sallan SE, et al. Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. *Cancer* 1988;61:1992–1998.
390. Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. *J Clin Oncol* 2002;20:842–849.
391. Prados MD, Wara WM, Edwards MS, et al. Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: early results of a pilot study. *Int J Radiat Oncol Biol Phys* 1994;28:431–438.
392. Carrie C, Muracciole X, Gomez F, et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. *Int J Radiat Oncol Biol Phys* 2005;63:711–716.
393. Fukunaga-Johnson N, Lee JH, Sandler HM, et al. Patterns of failure following treatment for medulloblastoma: is it necessary to treat the entire posterior fossa? *Int J Radiat Oncol Biol Phys* 1998;42:143–146.
394. Wolden SL, Dunkel IJ, Souweidane MM, et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. *J Clin Oncol* 2003;21:3079–3083.
395. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. *Lancet Oncol* 2006;7:813–820.
396. Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. *J Clin Oncol* 1999;17:2127–2136.
397. Bailey CC, Gnekow A, Wellek S, et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. *Med Pediatr Oncol* 1995;25:166–178.
398. St Clair WH, Adams JA, Bues M, et al. Advantage of protons compared to conventional X-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. *Int J Radiat Oncol Biol Phys* 2004;58:727–734.
399. Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). *Eur J Cancer* 1990;26:464–469.
400. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carboplatin, thiopeta, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children’s Cancer Group. *J Clin Oncol* 1998;16:222–228.
401. Geyer JR, Spoto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. *J Clin Oncol* 2005;23:7621–7631.
402. Timmermann B, Kortmann RD, Kuhl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children: results of the German HIT-SKK87 and HIT-SKK92 trials. *J Clin Oncol* 2006;24:1554–1560.
403. Dhall C, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. *Pediatr Blood Cancer* 2008;50:1169–1175.

404. Chi SN, Gardner S, Levy AS, et al. Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: a final update on Head Start II Regimen A2 intensified with high-dose methotrexate. *J Clin Oncol* 2007;25:539s.
405. Ashley DM, Merchant TE, Strother D, et al. Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma: Children's Oncology Group study P9934. *J Clin Oncol* 2012;30:3181–3186.
406. Hoppe-Hirsch E, Renier D, Lellouch-Tubiana A, et al. Medulloblastoma in childhood: progressive intellectual deterioration. *Childs Nerv Syst* 1990;6:60–65.
407. Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. *J Neurosurg* 1989;70:707–713.
408. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. *J Clin Oncol* 2005;23:5511–5519.
409. Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: population-based results from the United States and Sweden. *Cancer Causes Control* 1997;8:865–871.
410. Hoffman HJ. Pineal region tumors. *Prog Exp Tumor Res* 1987;30:281–288.
411. Sugiyama K, Uozumi T, Kiyu K, et al. Intracranial germ-cell tumor with synchronous lesions in the pineal and suprasellar regions: report of six cases and review of the literature. *Surg Neurol* 1992;38:114–120.
412. Reddy AT, Wellons JC 3rd, Allen JC, et al. Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus. *Neuro Oncol* 2004;6:127–133.
413. Pomarede R, Czernichow P, Finidori J, et al. Endocrine aspects and tumoral markers in intracranial germinoma: an attempt to delineate the diagnostic procedure in 14 patients. *J Pediatr* 1982;101:374–378.
414. Apuzzo M. *Surgery of the Third Ventricle*. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1998:1254.
415. Sawamura Y, de Tribolet N, Ishii N, et al. Management of primary intracranial germinomas: diagnostic surgery or radical resection? *J Neurosurg* 1997;87:262–266.
416. Regis J, Bouillot P, Rouby-Volot F, et al. Pineal region tumors and the role of stereotactic biopsy: review of the mortality, morbidity, and diagnostic rates in 370 cases. *Neurosurgery* 1996;39:907–912.
417. Pople IK, Athanasios TC, Sandeman DR, et al. The role of endoscopic biopsy and third ventriculostomy in the management of pineal region tumours. *Br J Neurosurg* 2001;15:305–311.
418. Wara WM, Jenkin RD, Evans A, et al. Tumors of the pineal and suprasellar region: Childrens Cancer Study Group treatment results 1960–1975: a report from Childrens Cancer Study Group. *Cancer* 1979;43:698–701.
419. Wolden SL, Wara WM, Larson DA, et al. Radiation therapy for primary intracranial germ-cell tumors. *Int J Radiat Oncol Biol Phys* 1995;32:943–949.
420. Haas-Kogan DA, Missett BT, Wara WM, et al. Radiation therapy for intracranial germ cell tumors. *Int J Radiat Oncol Biol Phys* 2003;56:511–518.
421. Bouffet E, Baranzelli MC, Patte C, et al. Combined treatment modality for intracranial germinomas: results of a multicentre SFOP experience. Societe Francaise d'Oncologie Pediatric. *Br J Cancer* 1999;79:1199–1204.
422. Buckner JC, Peethambaram PP, Smithson WA, et al. Phase II trial of primary chemotherapy followed by reduced-dose radiation for CNS germ cell tumors. *J Clin Oncol* 1999;17:933–940.
423. Merchant TE, Davis BJ, Sheldon JM, et al. Radiation therapy for relapsed CNS germinoma after primary chemotherapy. *J Clin Oncol* 1998;16:204–209.
424. Fuller BG, Kapp DS, Cox R. Radiation therapy of pineal region tumors: 25 new cases and a review of 208 previously reported cases. *Int J Radiat Oncol Biol Phys* 1994;28:229–245.
425. Allen JC, Kim JH, Packer RJ. Neoadjuvant chemotherapy for newly diagnosed germ-cell tumors of the central nervous system. *J Neurosurg* 1987;67:65–70.
426. Balmaceda C, Heller G, Rosenblum M, et al. Chemotherapy without irradiation—a novel approach for newly diagnosed CNS germ cell tumors: results of an international cooperative trial. The First International Central Nervous System Germ Cell Tumor Study. *J Clin Oncol* 1996;14:2908–2915.
427. Kellie SJ, Boyce H, Dunkel IJ, et al. Primary chemotherapy for intracranial nongerminomatous germ cell tumors: results of the second international CNS germ cell study group protocol. *J Clin Oncol* 2004;22:846–853.
428. Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. *J Neurosurg* 1997;86:446–455.
429. Broniscer A, Nicolaidis TP, Dunkel IJ, et al. High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. *Pediatr Blood Cancer* 2004;42:261–267.
430. Wilson C. Surgical management of endocrine-active pituitary adenomas. In: Walker MD, ed. *Oncology of the Nervous System*. New York: Springer; 1983:44.
431. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. *Semin Reprod Med* 2002;20:365–374.
432. Rand T, Kink E, Sator M, et al. MRI of microadenomas in patients with hyperprolactinaemia. *Neuroradiology* 1996;38:744–746.
433. Jane JA Jr, Thapar K, Kaptain GJ, et al. Pituitary surgery: transsphenoidal approach. *Neurosurgery* 2002;51:435–442.
434. Mortini P, Losa M, Barzaghi R, et al. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. *Neurosurgery* 2005;56:1222–1233.
435. Nomikos P, Ladar C, Fahlbusch R, et al. Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. *Acta Neurochir (Wien)* 2004;146:27–35.
436. Cappabianca P, Cavallo LM, Colao A, et al. Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas. *J Neurosurg* 2002;97:293–298.
437. Swearingen B, Biller BM, Barker FG 2nd, et al. Long-term mortality after transsphenoidal surgery for Cushing disease. *Ann Intern Med* 1999;130:821–824.
438. Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. *J Neurosurg* 2003;98:719–724.
439. Dickerman RD, Oldfield EH. Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery. *J Neurosurg* 2002;97:1343–1349.
440. Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. *J Neurosurg* 2005;102:1004–1012.
441. Greenman Y, Ouaknine C, Veshchev I, et al. Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. *Clin Endocrinol (Oxf)* 2003;58:763–769.
442. Honegger J, Prettin C, Feuerhake F, et al. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. *J Neurosurg* 2003;99:674–679.
443. Melmed S. Acromegaly. *N Engl J Med* 1990;322:966–977.
444. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. *J Clin Endocrinol Metab* 1997;82:3187–3191.
445. Suliman M, Jenkins R, Ross R, et al. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. *J Endocrinol Invest* 1999;22:409–418.
446. Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. *N Engl J Med* 1977;297:957–962.
447. Levy RP, Schulte RW, Slater JD, et al. Stereotactic radiosurgery—the role of charged particles. *Acta Oncol* 1999;38:165–169.
448. Mitsuomi M, Shrieve DC, Alexander E 3rd, et al. Initial clinical results of LINAC-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas. *Int J Radiat Oncol Biol Phys* 1998;42:573–580.
449. McCord MW, Buatti JM, Fennell EM, et al. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. *Int J Radiat Oncol Biol Phys* 1997;39:437–444.
450. Tsang RW, Brierley JD, Panzarella T, et al. Role of radiation therapy in clinical hormonally-active pituitary adenomas. *Radiother Oncol* 1996;41:45–53.
451. Zierhut D, Flentje M, Adolph J, et al. External radiotherapy of pituitary adenomas. *Int J Radiat Oncol Biol Phys* 1995;33:307–314.
452. Brada M, Ashley S, Ford D, et al. Cerebrovascular mortality in patients with pituitary adenoma. *Clin Endocrinol (Oxf)* 2002;57:713–717.
453. Breen P, Flickinger JC, Kondziolka D, et al. Radiotherapy for nonfunctional pituitary adenoma: analysis of long-term tumor control. *J Neurosurg* 1998;89:933–938.
454. Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. *J Clin Endocrinol Metab* 2005;90:800–804.
455. Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. *J Neurosurg* 2005;102:678–691.
456. Tishler RB, Loeffler JS, Lunsford LD, et al. Tolerance of cranial nerves of the cavernous sinus to radiosurgery. *Int J Radiat Oncol Biol Phys* 1993;27:215–221.
457. Attanasio R, Epaminonda P, Motti E, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. *J Clin Endocrinol Metab* 2003;88:3105–3112.
458. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. *J Neurosurg* 1998;88:1002–1008.
459. Kobayashi T, Mori Y, Uchiyama Y, et al. Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? *J Neurosurg* 2005;102:119–123.
460. Losa M, Valle M, Mortini P, et al. Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. *J Neurosurg* 2004;100:438–444.
461. Petrovich Z, Yu C, Giannotta SL, et al. Gamma knife radiosurgery for pituitary adenoma: early results. *Neurosurgery* 2003;53:51–59.
462. Schoenthaler R, Albright NW, Wara WM, et al. Re-irradiation of pituitary adenoma. *Int J Radiat Oncol Biol Phys* 1992;24:307–314.
463. Vance ML. Medical treatment of functional pituitary tumors. *Neurosurg Clin N Am* 2003;14:81–87.
464. Melmed S, Vance ML, Barkan AL, et al. Current status and future opportunities for controlling acromegaly. *Pituitary* 2002;5:185–196.
465. Parkinson C, Scarlett JA, Trainer PJ. Pegvisomant in the treatment of acromegaly. *Adv Drug Deliv Rev* 2003;55:1303–1314.



466. Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990–1994. *Neuro Oncol* 1999;1:14–25.
467. Larijani B, Bastanagh MH, Pajouhi M, et al. Presentation and outcome of 93 cases of craniopharyngioma. *Eur J Cancer Care (Engl)* 2004;13:11–15.
468. Teo C. Application of endoscopy to the surgical management of craniopharyngiomas. *Childs Nerv Syst* 2005;21:696–700.
469. Albright AL, Hadjippanayis CG, Lunsford LD, et al. Individualized treatment of pediatric craniopharyngiomas. *Childs Nerv Syst* 2005;21:649–654.
470. Stripp DC, Maity A, Janss AJ, et al. Surgery with or without radiation therapy in the management of craniopharyngiomas in children and young adults. *Int J Radiat Oncol Biol Phys* 2004;58:714–720.
471. Karavitaki N, Brufani C, Warner JT, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. *Clin Endocrinol (Oxf)* 2005;62:397–409.
472. Pollock BE, Lunsford LD, Kondziolka D, et al. Phosphorus-32 intracavitary irradiation of cystic craniopharyngiomas: current technique and long-term results. *Int J Radiat Oncol Biol Phys* 1995;33:437–446.
473. Fischer EG, Welch K, Belli JA, et al. Treatment of craniopharyngiomas in children: 1972–1981. *J Neurosurg* 1985;62:496–501.
474. Richmond IL, Wara WM, Wilson CB. Role of radiation therapy in the management of craniopharyngiomas in children. *Neurosurgery* 1980;6:513–517.
475. Wen BC, Hussey DH, Staples J, et al. A comparison of the roles of surgery and radiation therapy in the management of craniopharyngiomas. *Int J Radiat Oncol Biol Phys* 1989;16:17–24.
476. Kalapurakal JA, Goldman S, Hsieh YC, et al. Clinical outcome in children with craniopharyngioma treated with primary surgery and radiotherapy deferred until relapse. *Med Pediatr Oncol* 2003;40:214–218.
477. Hetelekidis S, Barnes PD, Tao ML, et al. 20-year experience in childhood craniopharyngioma. *Int J Radiat Oncol Biol Phys* 1993;27:189–195.
478. Merchant TE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude Children's Research Hospital experience 1984–2001. *Int J Radiat Oncol Biol Phys* 2002;53:533–542.
479. Schulz-Ertner D, Frank C, Herfarth KK, et al. Fractionated stereotactic radiotherapy for craniopharyngiomas. *Int J Radiat Oncol Biol Phys* 2002;54:1114–1120.
480. Varlotto JM, Flickinger JC, Kondziolka D, et al. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. *Int J Radiat Oncol Biol Phys* 2002;54:492–499.
481. Ulfarson E, Lindquist C, Roberts M, et al. Gamma knife radiosurgery for craniopharyngiomas: long-term results in the first Swedish patients. *J Neurosurg* 2002;97:613–622.
482. Jackson AS, St George EJ, Hayward RJ, et al. Stereotactic radiosurgery. XVII: Recurrent intrasellar craniopharyngioma. *Br J Neurosurg* 2003;17:138–143.
483. Kobayashi T, Kida Y, Mori Y, et al. Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. *J Neurosurg* 2005;103:482–488.
484. Propp JM, McCarthy BJ, Davis FG, et al. Descriptive epidemiology of vestibular schwannomas. *Neuro Oncol* 2006;8:1–11.
485. Stangerup SE, Tos M, Caye-Thomasen P, et al. Increasing annual incidence of vestibular schwannoma and age at diagnosis. *J Laryngol Otol* 2004;118:622–627.
486. Anderson TD, Loevner LA, Bigelow DC, et al. Prevalence of unsuspected acoustic neuroma found by magnetic resonance imaging. *Otolaryngol Head Neck Surg* 2000;122:643–646.
487. Lin D, Hegarty JL, Fischbein NJ, et al. The prevalence of “incidental” acoustic neuroma. *Arch Otolaryngol Head Neck Surg* 2005;131:241–244.
488. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. *Neurology* 2002;59:1759–1765.
489. Jaaskelainen J, Paetau A, Pykko I, et al. Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases. *J Neurosurg* 1994;80:541–547.
490. Samii M, Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. *Neurosurgery* 1997;40:11–21.
491. Doyle KJ. Is there still a role for auditory brainstem response audiometry in the diagnosis of acoustic neuroma? *Arch Otolaryngol Head Neck Surg* 1999;125:232–234.
492. Rutherford SA, King AT. Vestibular schwannoma management: What is the 'best' option? *Br J Neurosurg* 2005;19:309–316.
493. Charabi S, Tos M, Thomsen J, et al. Vestibular schwannoma growth—long-term results. *Acta Otolaryngol Suppl* 2000;543:7–10.
494. Eldridge R, Parry D. Vestibular schwannoma (acoustic neuroma). Consensus development conference. *Neurosurgery* 1992;30:962–964.
495. Sarmiento JM, Patel S, Mukherjee D, et al. Improving outcomes in patients with vestibular schwannomas: microsurgery versus radiosurgery. *J Neurosurg Sci* 2013;57:23–44.
496. Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. *J Neuropathol Exp Neurol* 1993;52:106–113.
497. Gornley WB, Sekhar LN, Wright DC, et al. Acoustic neuromas: results of current surgical management. *Neurosurgery* 1997;41:50–58.
498. Barker FG 2nd, Carter BS, Ojemann RG, et al. Surgical excision of acoustic neuroma: patient outcome and provider caseload. *Laryngoscope* 2003;113:1332–1343.
499. Buchman CA, Chen DA, Flannagan P, et al. The learning curve for acoustic tumor surgery. *Laryngoscope* 1996;106:1406–1411.
500. Welling DB, Slater PW, Thomas RD, et al. The learning curve in vestibular schwannoma surgery. *Am J Otol* 1999;20:644–648.
501. Moriyama T, Fukushima T, Asaoka K, et al. Hearing preservation in acoustic neuroma surgery: importance of adhesion between the cochlear nerve and the tumor. *J Neurosurg* 2002;97:337–340.
502. Sanna M, Taibah A, Russo A, et al. Perioperative complications in acoustic neuroma (vestibular schwannoma) surgery. *Otol Neurotol* 2004;25:379–386.
503. Ryzenman JM, Pensak ML, Tew JM Jr. Headache: a quality of life analysis in a cohort of 1,657 patients undergoing acoustic neuroma surgery, results from the acoustic neuroma association. *Laryngoscope* 2005;115:703–711.
504. Tufarelli D, Meli A, Alesii A, et al. Quality of life after acoustic neuroma surgery. *Otol Neurotol* 2006;27:403–409.
505. Kondziolka D, Lunsford LD, McLaughlin MR, et al. Long-term outcomes after radiosurgery for acoustic neuromas. *N Engl J Med* 1998;339:1426–1433.
506. Flickinger JC, Kondziolka D, Niranjan A, et al. Results of acoustic neuroma radiosurgery: an analysis of 5 years' experience using current methods. *J Neurosurg* 2001;94:1–6.
507. Chopra R, Kondziolka D, Niranjan A, et al. Long-term follow-up of acoustic schwannoma radiosurgery with marginal tumor doses of 12 to 13 Gy. *Int J Radiat Oncol Biol Phys* 2007;68:845–851.
508. Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. *Neurosurgery* 2006;59:77–85.
509. Williams JA. Fractionated stereotactic radiotherapy for acoustic neuromas. *Int J Radiat Oncol Biol Phys* 2002;54:500–504.
510. Meijer OW, Vandertop WP, Baayen JC, et al. Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. *Int J Radiat Oncol Biol Phys* 2003;56:1390–1396.
511. Andrews DW, Suarez O, Goldman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. *Int J Radiat Oncol Biol Phys* 2001;50:1265–1278.
512. Fuss M, Debus J, Lohr F, et al. Conventionally fractionated stereotactic radiotherapy (FSRT) for acoustic neuromas. *Int J Radiat Oncol Biol Phys* 2000;48:1381–1387.
513. Koh ES, Millar BA, Menard C, et al. Fractionated stereotactic radiotherapy for acoustic neuroma: single-institution experience at The Princess Margaret Hospital. *Cancer* 2007;109:1203–1210.
514. Sawamura Y, Shirato H, Sakamoto T, et al. Management of vestibular schwannoma by fractionated stereotactic radiotherapy and associated cerebrospinal fluid malabsorption. *J Neurosurg* 2003;99:685–692.
515. Hasegawa T, Kida Y, Yoshimoto M, et al. Evaluation of tumor expansion after stereotactic radiosurgery in patients harboring vestibular schwannomas. *Neurosurgery* 2006;58:1119–1128.
516. Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. *Neurosurgery* 2006;58:241–248.
517. Bari ME, Forster DM, Kemeny AA, et al. Malignancy in a vestibular schwannoma. Report of a case with central neurofibromatosis, treated by both stereotactic radiosurgery and surgical excision, with a review of the literature. *Br J Neurosurg* 2002;16:284–289.
518. Loeffler JS, Niemierko A, Chapman PH. Second tumors after radiosurgery: tip of the iceberg or a bump in the road? *Neurosurgery* 2003;52:1436–1440.
519. Ito T, Tsutsumi T, Ohno K, et al. Intracranial angiosarcoma arising from a schwannoma. *J Laryngol Otol* 2007;121:68–71.
520. Friedman RA, Brackmann DE, Hitselberger WE, et al. Surgical salvage after failed irradiation for vestibular schwannoma. *Laryngoscope* 2005;115:1827–1832.
521. Plotkin SR, Singh MA, O'Donnell CC, et al. Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. *Nat Clin Pract Oncol* 2008;5:487–491.
522. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. *N Engl J Med* 2009;361:358–367.
523. Mautner VF, Nguyen R, Kuita H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. *Neuro Oncol* 2010;12:14–18.
524. Farrior JB 3rd, Hyams VJ, Benke RH, et al. Carcinoid apudoma arising in a glomus jugulare tumor: review of endocrine activity in glomus jugulare tumors. *Laryngoscope* 1980;90:110–119.
525. Springate SC, Weichselbaum RR. Radiation or surgery for chemodectoma of the temporal bone: a review of local control and complications. *Head Neck* 1990;12:303–307.
526. Hinerman RW, Mendenhall WM, Amdur RJ, et al. Definitive radiotherapy in the management of chemodectomas arising in the temporal bone, carotid body, and glomus vagale. *Head Neck* 2001;23:363–371.

527. Gottfried ON, Liu JK, Couldwell WT. Comparison of radiosurgery and conventional surgery for the treatment of glomus jugulare tumors. *Neurosurg Focus* 2004;17:E4.
528. Sheehan J, Kondziolka D, Flickinger J, et al. Gamma knife surgery for glomus jugulare tumors: an intermediate report on efficacy and safety. *J Neurosurg* 2005;102:241–246.
529. Guss ZD, Batra S, Limb CJ, et al. Radiosurgery of glomus jugulare tumors: a meta-analysis. *Int J Radiat Oncol Biol Phys* 2011;81:e497–e502.
530. Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. *Q J Med* 1990;77:1151–1163.
531. Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. *Surv Ophthalmol* 2001;46:117–142.
532. Wanebo JE, Lonser RR, Glenn GM, et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. *J Neurosurg* 2003;98:82–94.
533. Acikalin MF, Oner U, Tel N, et al. Supratentorial hemangioblastoma: a case report and review of the literature. *Arch Pathol Lab Med* 2003;127:e382–e384.
534. Weil RJ, Lonser RR, DeVroom HL, et al. Surgical management of brainstem hemangioblastomas in patients with von Hippel-Lindau disease. *J Neurosurg* 2003;98:95–105.
535. Vougioukas VI, Glasker S, Hubbe U, et al. Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients. *Childs Nerv Syst* 2006;22:1149–1153.
536. Smalley SR, Schomberg PJ, Earle JD, et al. Radiotherapeutic considerations in the treatment of hemangioblastomas of the central nervous system. *Int J Radiat Oncol Biol Phys* 1990;18:1165–1171.
537. Patrice SJ, Sneed PK, Flickinger JC, et al. Radiosurgery for hemangioblastoma: results of a multiinstitutional experience. *Int J Radiat Oncol Biol Phys* 1996;35:493–499.
538. Asthagiri AR, Mehta CU, Zach L, et al. Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. *Neuro Oncol* 2010;12:80–86.
539. Jonasch E, McCutcheon IE, Waguespack SG, et al. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. *Ann Oncol* 2011;22:2661–2666.
540. Salisbury JR. The pathology of the human notochord. *J Pathol* 1993;171:253–255.
541. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973–1995. *Cancer Causes Control* 2001;12:1–11.
542. Gottschalk D, Fehn M, Patt S, et al. Matrix gene expression analysis and cellular phenotyping in chordoma reveals focal differentiation pattern of neoplastic cells mimicking nucleus pulposus development. *Am J Pathol* 2001;158:1571–1578.
543. Holton JL, Steel T, Luxsuwong M, et al. Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index. *Neuropathol Appl Neurobiol* 2000;26:497–503.
544. Rosenberg AE, Nielsen GP, Keel SB, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. *Am J Surg Pathol* 1999;23:1370–1378.
545. Crocckard HA, Cheeseman A, Steel T, et al. A multidisciplinary team approach to skull base chondrosarcomas. *J Neurosurg* 2001;95:184–189.
546. Volpe NJ, Liebsch NJ, Munzenrider JE, et al. Neuro-ophthalmologic findings in chordoma and chondrosarcoma of the skull base. *Am J Ophthalmol* 1993;115:97–104.
547. Pamiir MN, Ozduman K. Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas. *Eur J Radiol* 2006;58:461–470.
548. Erdem E, Angtuaco EC, Van Hemert R, et al. Comprehensive review of intracranial chordoma. *Radiographics* 2003;23:995–1009.
549. Mendenhall WM, Mendenhall CM, Lewis SB, et al. Skull base chordoma. *Head Neck* 2005;27:159–165.
550. Fraser JF, Nyquist GG, Moore N, et al. Endoscopic endonasal transclival resection of chordomas: operative technique, clinical outcome, and review of the literature. *J Neurosurg* 2010;112:1061–1069.
551. Stippler M, Gardner PA, Snyderman CH, et al. Endoscopic endonasal approach for clival chordomas. *Neurosurgery* 2009;64:268–277.
552. al-Mefty O, Borba LA. Skull base chordomas: a management challenge. *J Neurosurg* 1997;86:182–189.
553. Tzortzidis F, Elahi F, Wright D, et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. *Neurosurgery* 2006;59:230–237.
554. Gay E, Sekhar LN, Rubinstein E, et al. Chordomas and chondrosarcomas of the cranial base: results and follow-up of 60 patients. *Neurosurgery* 1995;36:887–896.
555. Debuss J, Schulz-Ertner D, Schad L, et al. Stereotactic fractionated radiotherapy for chordomas and chondrosarcomas of the skull base. *Int J Radiat Oncol Biol Phys* 2000;47:591–596.
556. Muthukumar N, Kondziolka D, Lunsford LD, et al. Stereotactic radiosurgery for chordoma and chondrosarcoma: further experiences. *Int J Radiat Oncol Biol Phys* 1998;41:387–392.
557. Krishnan S, Foote RL, Brown PD, et al. Radiosurgery for cranial base chordomas and chondrosarcomas. *Neurosurgery* 2005;56:777–784.
558. Hoch BL, Nielsen GP, Liebsch NJ, et al. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases. *Am J Surg Pathol* 2006;30:811–818.
559. Hug EB, Loreda LN, Slater JD, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. *J Neurosurg* 1999;91:432–439.
560. Igaki H, Tokuyue K, Okumura T, et al. Clinical results of proton beam therapy for skull base chordoma. *Int J Radiat Oncol Biol Phys* 2004;60:1120–1126.
561. Noel G, Feuvret L, Calugaru V, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. *Acta Oncol* 2005;44:700–708.
562. Austin JP, Urie MM, Cardenas G, et al. Probable causes of recurrence in patients with chordoma and chondrosarcoma of the base of skull and cervical spine. *Int J Radiat Oncol Biol Phys* 1993;25:439–444.
563. Ares C, Hug EB, Lomax AJ, et al. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. *Int J Radiat Oncol Biol Phys* 2009;75:1111–1118.
564. Weber DC, Rutz HP, Pedroni ES, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. *Int J Radiat Oncol Biol Phys* 2005;63:401–409.
565. Schulz-Ertner D, Nikoghosyan A, Thilmann C, et al. Carbon ion radiotherapy for chordomas and low-grade chondrosarcomas of the skull base. Results in 67 patients. *Strahlenther Onkol* 2003;179:598–605.
566. Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. *Neurosurg Rev* 2010;33:155–165.
567. Stacchiotti S, Longhi A, Ferraresi V, et al. Phase II study of imatinib in advanced chordoma. *J Clin Oncol* 2012;30:914–920.
568. Stacchiotti S, Marrari A, Tamborini E, et al. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009;20:1886–1894.
569. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. *J Clin Oncol* 2010;28:1995–2001.
570. Pencanalet P, Sainte-Rose C, Lellouch-Tubiana A, et al. Papillomas and carcinomas of the choroid plexus in children. *J Neurosurg* 1998;88:521–528.
571. McEvoy AW, Harding BN, Phipps KP, et al. Management of choroid plexus tumours in children: 20 years experience at a single neurosurgical centre. *Pediatr Neurosurg* 2000;32:192–199.
572. Wrede B, Liu P, Ater J, et al. Second surgery and the prognosis of choroid plexus carcinoma—results of a meta-analysis of individual cases. *Anticancer Res* 2005;25:4429–4433.
573. Krishnan S, Brown PD, Scheithauer BW, et al. Choroid plexus papillomas: a single institutional experience. *J Neurooncol* 2004;68:49–55.
574. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. *N Engl J Med* 1993;328:1725–1731.
575. Wrede B, Liu P, Wolff JE. Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. *J Neurooncol* 2007;85:345–351.
576. Epstein FJ, Farmer JP, Freed D. Adult intramedullary spinal cord ependymomas: the result of surgery in 38 patients. *J Neurosurg* 1993;79:204–209.
577. Jallo GI, Freed D, Epstein F. Intramedullary spinal cord tumors in children. *Childs Nerv Syst* 2003;19:641–649.
578. Linstadt DE, Wara WM, Leibel SA, et al. Postoperative radiotherapy of primary spinal cord tumors. *Int J Radiat Oncol Biol Phys* 1989;16:1397–1403.
579. Waldron JN, Laperriere NJ, Jaakkimainen L, et al. Spinal cord ependymomas: a retrospective analysis of 59 cases. *Int J Radiat Oncol Biol Phys* 1993;27:223–229.
580. Barone BM, Elvidge AR. Ependymomas. A clinical survey. *J Neurosurg* 1970;33:428–438.
581. Shuman RM, Alvord EC Jr, Leech RW. The biology of childhood ependymomas. *Arch Neurol* 1975;32:731–739.
582. Whitaker SJ, Bessell EM, Ashley SE, et al. Postoperative radiotherapy in the management of spinal cord ependymoma. *J Neurosurg* 1991;74(5):720–728.
583. Wen BC, Hussey DH, Hitchon PW, et al. The role of radiation therapy in the management of ependymomas of the spinal cord. *Int J Radiat Oncol Biol Phys* 1991;20:781–786.
584. Lee HK, Chang EL, Fuller GN, et al. The prognostic value of neurologic function in astrocytic spinal cord glioma. *Neuro Oncol* 2003;5:208–213.
585. Santi M, Mena H, Wong K, et al. Spinal cord malignant astrocytomas. Clinicopathologic features in 36 cases. *Cancer* 2003;98:554–561.